Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NOVAVAX INC (NVAX)

Novavax to receive $125 million milestone after Sanofi starts Phase 3 flu-COVID trial

Positive Impact 3 of 5 product/contract Written later

Novavax said Sanofi dosed the fifth patient in a Phase 3 influenza-COVID-19 combination vaccine trial in the European Union on October 28, 2026, using Novavax's COVID-19 component. That dosing triggers a $125 million milestone payment under the companies' collaboration agreement, which Novavax expects to receive by the first quarter of 2027.

Key points

  • $125 million milestone payment from Sanofi triggered by dosing of the fifth patient on October 28, 2026
  • Payment expected by the first quarter of 2027
  • Additional eligible payments include a $75 million milestone on manufacturing technology transfer, anticipated mid-2027, and a $225 million milestone on a U.S. launch of a combination vaccine
  • CEO John C. Jacobs said the partnership has generated over $1 billion in revenue for Novavax to date

The filing

CompanyNOVAVAX INC (NVAX)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:30 PM ET
Accession number0001104659-26-120221

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.